Hedtke Shannon M, Kode Anusha, Ukety Tony O, Mande Jöel L, Abhafule Germain M, Raciu Anuarite A, Uvon Claude B, Jada Stephen R, Hotterbeekx An, Siewe Fodjo Joseph Nelson, Mitreva Makedonka, Sebit Wilson, Colebunders Robert, Grant Warwick N, Kuesel Annette C
Department of Environment and Genetics, La Trobe University, Bundoora, VIC 3086, Australia.
Centre de Recherche en Maladies Tropicales (CRMT), Bunia P.O. Box 143, Democratic Republic of the Congo.
Trop Med Infect Dis. 2023 Sep 12;8(9):445. doi: 10.3390/tropicalmed8090445.
WHO and endemic countries target elimination of transmission of , the parasite causing onchocerciasis. Population genetic analysis of may provide data to improve the evidence base for decisions on when, where, and for how long to deploy which interventions and post-intervention surveillance to achieve elimination. Development of necessary methods and tools requires parasites suitable for genetic analysis. Based on our experience with microfilariae obtained from different collaborators, we developed a microfilariae transfer procedure for large-scale studies in the Democratic Republic of Congo (DRC) comparing safety and efficacy of ivermectin, the mainstay of current onchocerciasis elimination strategies, and moxidectin, a new drug. This procedure is designed to increase the percentage of microfilariae in skin snips suitable for genetic analysis, improve assignment to metadata, and minimize time and materials needed by the researchers collecting the microfilariae. Among 664 microfilariae from South Sudan, 35.7% and 39.5% failed the mitochondrial and nuclear qPCR assay. Among the 576 microfilariae from DRC, 16.0% and 16.7% failed these assays, respectively. This difference may not only be related to the microfilariae transfer procedure but also to other factors, notably the ethanol concentration in the tubes in which microfilariae were stored (64% vs. ≥75%).
世界卫生组织和各流行国家的目标是消除导致盘尾丝虫病的寄生虫——盘尾丝虫的传播。对盘尾丝虫进行群体遗传分析可为决策提供数据,以完善关于何时、何地以及针对何种情况部署何种干预措施和干预后监测以实现消除目标的证据基础。开发必要的方法和工具需要适合进行遗传分析的寄生虫。基于我们从不同合作者处获取微丝蚴的经验,我们开发了一种微丝蚴转移程序,用于在刚果民主共和国开展大规模研究,比较伊维菌素(当前盘尾丝虫病消除策略的主要药物)和莫西菌素(一种新药)的安全性和有效性。该程序旨在提高适合进行遗传分析的皮肤切片中微丝蚴的比例,改善元数据的分配,并尽量减少收集微丝蚴的研究人员所需的时间和材料。在来自南苏丹的664条微丝蚴中,35.7%和39.5%的微丝蚴线粒体和核定量聚合酶链反应检测未通过。在来自刚果民主共和国的576条微丝蚴中,分别有16.0%和16.7%的微丝蚴检测未通过。这种差异可能不仅与微丝蚴转移程序有关,还与其他因素有关,尤其是储存微丝蚴的试管中的乙醇浓度(64%对≥75%)。